Preclinical vs. Clinical Studies Explained
Preclinical and Clinical Studies: The Difference
Preclinical studies test a drug candidate before people come into contact with it; clinical studies examine it in humans according to an approved protocol. The difference between preclinical and clinical studies is therefore not only the testing setting, but above all the objective, test system, endpoints, and regulatory threshold. Without an adequate preclinical data package, there is no first-in-human study. For orientation – from the basic question What are research peptides? to the first-in-human study – three questions help: What is being tested, in whom is it being tested, and what evidence is needed for the next development step?
Objective, test system, endpoints: the key dividing lines
| Aspect | Preclinical | Clinical |
|---|---|---|
| Primary objective | Clarify biological effect, feasibility, and safety boundaries before human exposure | Assess safety, dosing, and clinical benefit in humans |
| Test system | In vitro, ex vivo, and in vivo models | Healthy volunteers or patients |
| Typical data | Mechanism, ADME/PK, pharmacology, toxicology | Adverse events, clinical endpoints, comparison with placebo or standard therapy |
| Decision function | Justifies whether and how a study in humans can start | Supports approval decisions and subsequent clinical use |
To put laboratory approaches into context, the overview of In‑vitro and in‑vivo models is helpful.
From drug candidate to human study
-
Discovery and optimization: First, candidates are identified and optimized for stability, target binding, and basic properties.
-
Preclinical testing: This is followed by nonclinical data on effect, pharmacokinetics, and safety, as also categorized in the Glossary of research peptides. Many candidates drop out here, even if initial lab findings look promising.
-
Preparing the first study in humans: Preclinical results shape starting dose, safety monitoring, and the go/no-go decision for first-in-human studies.
-
Clinical phases I to III: Then testing proceeds in humans stepwise, first focusing on tolerability, later on efficacy and comparability. Many programs also fail in these phases.
-
Approval: Only when benefits, risks, and quality are sufficiently documented can approval be sought.
-
Phase IV and pharmacovigilance: After market entry, long-term safety, rare risks, and real-world data continue to be monitored.
What is assessed in the preclinical phase
A preclinical study is part of the nonclinical development of a drug candidate. It examines efficacy signals, pharmacological properties, and dose–response relationships in suitable laboratory and model systems. These include, for example, binding vs. functional assays. Typically, pharmacokinetics and ADME—absorption, distribution, metabolism, and excretion—are also included. Depending on the product and use case, safety testing for peptides such as toxicology, genotoxicity, or reproductive toxicity also becomes relevant. Importantly, the preclinical phase is not a single test but a data package. The endpoint is not a clinical efficacy statement, but a more robust assessment of benefits, risks, and open questions before human exposure.
What prerequisites must be met before the first study in humans
Before a first-in-human study, preclinical findings, expected exposure, safety margins, and the planned starting dose are assessed together. Positive lab data alone are not sufficient. In addition, the quality of the investigational product, manufacturing and documentation status, and the overall risk–benefit assessment must be robust. A human study also requires a clear protocol, regulatory approvals, and a favorable ethics opinion. Safety monitoring, predefined stopping rules, and clear responsibilities are also part of it. This is precisely where the regulatory shift occurs: nonclinical evidence becomes a controlled human research project that must be planned, monitored, and documented according to fixed standards.
How clinical studies are structured
Clinical studies usually follow a phase logic, although not every study has the same design. Comparison arm, blinding, and population are always determined by the scientific question and the ethical framework.
| Phase | Guiding question | Typical participants | Common endpoints |
|---|---|---|---|
| Phase I | How well tolerated is the candidate, and which dose ranges are appropriate? | Often healthy volunteers; for certain risks or indications, also patients | Safety, tolerability, pharmacokinetics, early dose data |
| Phase II | Are there initial signs of efficacy, and which dose should be studied further? | Patients with the target disease | Early efficacy, dose finding, additional safety data |
| Phase III | Is the benefit confirmed compared with placebo or standard therapy? | Larger, more strictly defined patient groups | Clinical endpoints, comparative data, broader safety profile |
| Phase IV | How does the product perform in routine care after approval? | Broader use after market entry | Long-term safety, rare adverse events, additional use data |
In the course of development, the number of participants and the closeness to real-world care generally increase, while the focus shifts from safety limits toward clinical benefit and long-term safety.
RCTs: when comparison is randomized and controlled
In a randomized controlled trial (RCT), participants are assigned to groups at random. This is intended to distribute known and unknown influencing factors as evenly as possible and reduce bias. Depending on the question, the control group receives placebo, standard therapy, or an active comparator; blinding can reduce additional sources of bias. RCTs are especially important in confirmatory clinical studies. Still, not every clinical question requires a classic RCT design. The evidential value also always depends on the endpoints, inclusion and exclusion criteria, and rigorous conduct.
How we situate the topic in peptide research
We operate at 24Peptides in a research-use context and provide research peptides and background knowledge for nonclinical work, not products for human use. Especially in preclinical research, identity, purity, and contamination control are critical, because otherwise the starting material alone can skew interpretation. That is why each batch is independently tested by us, including purity, identity, endotoxins, bioburden, and heavy metals, and we publish a COA for every batch. Depending on the batch, methods such as HPLC or LC–MS are also documented in the analysis reports. Additional content on storage, reconstitution, half-life, and study design helps situate peptide research more rigorously.
Frequently asked questions about clinical studies
The following questions no longer concern the core difference between preclinical and clinical research, but rather participation in human studies. The distinction is important: compensation or reimbursement of expenses only applies to studies with human participants. In the preclinical phase there is no human participation, but lab and model research.
How much do you get paid in a clinical study?
In clinical studies, it is usually not a salary but compensation for expenses. It is intended to offset time, travel, inconveniences, and the burden of procedures. Its amount depends on study duration, number of visits, type of procedures, any inpatient stays, and the respective risk. Healthy volunteers in early phases and patients in therapeutic studies often receive different types or levels of compensation. The statements in the study documents and the applicable ethical and legal requirements are always binding.
Is there compensation for clinical studies?
Often yes, but not in every study and not always in the same form. Possible options include reimbursement for travel costs, meals, parking fees, or a flat compensation for time. What matters is that a payment must not unduly influence voluntary consent. Therefore, compensation in clinical studies is usually considered as part of the protocol and ethics review. Whether payment is made at all and how it is arranged is usually stated in the study information and in the consent documents for participants.
